DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.95

Change

+0.09 (+1.15)%

Market Cap

USD 0.17B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.18 (+0.18%)

USD 16.85B
IVV:AU iShares Core S&P 500 AUD

+0.41 (+0.64%)

USD 9.99B
VGS:AU Vanguard MSCI International Sh..

+0.91 (+0.65%)

USD 9.45B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.29 (+0.50%)

USD 6.99B
IOZ:AU Ishares Core S&P/Asx 200

+0.10 (+0.30%)

USD 6.22B
STW:AU SPDR® S&P/ASX 200 Fund

+0.21 (+0.28%)

USD 5.69B
NDQ:AU Betashares Nasdaq 100

+0.41 (+0.80%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.12 (+0.28%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.30 (+0.22%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+2.30 (+0.49%)

USD 4.71B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.38% 21% F 56% F
Dividend Return 3.15% 46% F 38% F
Total Return 3.53% 20% F 56% F
Trailing 12 Months  
Capital Gain 1.53% 26% F 57% F
Dividend Return 3.19% 43% F 35% F
Total Return 4.72% 24% F 56% F
Trailing 5 Years  
Capital Gain 20.27% 63% D 70% C-
Dividend Return 11.04% 28% F 27% F
Total Return 31.31% 54% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 7.04% 71% C- 55% F
Dividend Return 8.66% 69% C- 54% F
Total Return 1.62% 57% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 8.43% 65% D 92% A
Risk Adjusted Return 102.69% 95% A 97% N/A
Market Capitalization 0.17B 34% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.